Clinical Decision Support and Palivizumab: A Means to Protect from Respiratory Syncytial Virus.

ABSTRACT:

Background and objectives

Palivizumab can reduce hospitalizations due to respiratory syncytial virus (RSV), but many eligible infants fail to receive the full 5-dose series. The efficacy of clinical decision support (CDS) in fostering palivizumab receipt has not been studied. We sought a comprehensive solution for identifying eligible patients and addressing barriers to palivizumab administration.

Methods

We developed workflow and CDS tools targeting patient identification and palivizumab administration. We randomized 10 practices to receive palivizumab-focused CDS and 10 to receive comprehensive CDS for premature infants in a 3-year longitudinal cluster-randomized trial with 2 baseline and 1 intervention RSV seasons.

Results

There were 356 children eligible to receiv

SUBMITTER: Utidjian LH 

PROVIDER: S-EPMC4704044 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature